ClinicalTrials.gg
CompletedNCT01089543Updated Dec 24, 2013Results posted

A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204)

A Phase 2 interventional study of Rabeprazole and Rabeprazole in Functional Dyspepsia, sponsored by Eisai Co., Ltd.. Completed at 46 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-12-24.

Sponsored by Eisai Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
338
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the efficacy and safety of rabeprazole compared to placebo in Japanese subjects with Functional Dyspepsia.

02

Conditions studied

  • Functional Dyspepsia

Browse trials for

Keywords

  • dyspepsia
  • rabeprazole
  • Japan
03

In context

Dyspepsia

372 studies on the registry are indexed under Dyspepsia; 66 are open to participants now.

This study's enrollment of 338 is above the median of 89 across 302 interventional studies indexed under Dyspepsia.

Browse Dyspepsia studies →

Lead sponsor

Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Participants diagnosed as Functional Dyspepsia according to Rome III criteria.

Exclusion criteria

Exclusion criteria:

  • Participants with neuropsychiatric disorder.
  • Participants diagnosed with irritable bowel syndrome, inflammatory bowel disease and serious constipation.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
338 participants (actual)

Study arms

  • Experimental
    Rabeprazole 10 mg

    Drug: Rabeprazole

  • Experimental
    Rabeprazole 20 mg

    Drug: Rabeprazole

  • Experimental
    Rabeprazole 40 mg

    Drug: Rabeprazole

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Rabeprazole 10 mg tablet taken orally once daily after breakfast for 8 weeks.

    Also known as: E3810

  • Rabeprazole 20 mg tablet taken orally once daily after breakfast for 8 weeks.

    Also known as: E3810

  • Rabeprazole 40 mg tablet taken orally once daily after breakfast for 8 weeks.

    Also known as: E3810

  • DrugPlacebo

    Rabeprazole Placebo tablet taken orally once daily after breakfast for 8 weeks.

    Also known as: E3810

06

What researchers measure

Primary outcomes

  1. Rate of Complete Dyspepsia Symptom Relief

    The rate of complete dyspepsia symptom relief according to the Dyspepsia Symptom Questionnaire (DSQ) was defined as a score of 1 for all four major dyspeptic symptoms at week 8 and according to the diary defined as all four dyspepsia symptoms recorded absent during the 7 days prior to week 8. Values presented as percentage of participants.

    Time frame: Up to 8 Weeks (including 7 days prior)

Secondary outcomes

  1. Rate of Satisfactory Symptom Relief

    The rate of satisfactory symptom relief according to the DSQ defined as scores of \<= 2 for all four major dyspepsia symptoms at week 8 and the diary recordings defined as a frequency of \<= 1 day for all four major dyspepsia symptoms during the 7 days before week 8. Lastly, treatment success according to the participants' impression questionnaire where participants answered "yes" or "no" when asked if given the choice, whether they would want to continue to take the study drug after clinical trial completion. Values presented as percentage of participants.

    Time frame: Up to 8 Weeks (including 7 days prior)

07

Results

Posted Nov 19, 2013

Participant flow

This study was recruited at 66 centers in Japan during the period of 21-April-2010 to 12-Aug-2011.

Participant flow — Overall Study
MilestoneRabeprazole 10 mgRabeprazole 20 mgRabeprazole 40 mgPlacebo
Started84858485
Completed81818183
Not completed3432
Withdrew: Withdrawal by subject2331
Withdrew: Physician decision1001
Withdrew: Adverse event0100

Outcome measures

PrimaryRate of Complete Dyspepsia Symptom Relief

The rate of complete dyspepsia symptom relief according to the Dyspepsia Symptom Questionnaire (DSQ) was defined as a score of 1 for all four major dyspeptic symptoms at week 8 and according to the diary defined as all four dyspepsia symptoms recorded absent during the 7 days prior to week 8. Values presented as percentage of participants.

Time frame:
Up to 8 Weeks (including 7 days prior)
Reported as:
Number · Percentage of Participants
Rate of Complete Dyspepsia Symptom Relief
Percentage of ParticipantsRabeprazole 10 mgRabeprazole 20 mgRabeprazole 40 mgPlacebo
DSQ (n= 76, n= 75, n= 74, n= 78)22.429.327.017.9
Diary Recordings (n= 77, n= 76, n=74, n=80)22.128.927.017.5
SecondaryRate of Satisfactory Symptom Relief

The rate of satisfactory symptom relief according to the DSQ defined as scores of \<= 2 for all four major dyspepsia symptoms at week 8 and the diary recordings defined as a frequency of \<= 1 day for all four major dyspepsia symptoms during the 7 days before week 8. Lastly, treatment success according to the participants' impression questionnaire where participants answered "yes" or "no" when asked if given the choice, whether they would want to continue to take the study drug after clinical trial completion. Values presented as percentage of participants.

Time frame:
Up to 8 Weeks (including 7 days prior)
Reported as:
Number · Percentage of participants
Rate of Satisfactory Symptom Relief
Percentage of participantsRabeprazole 10 mgRabeprazole 20 mgRabeprazole 40 mgPlacebo
DSQ (n=76, n=75, n=74, n=78)42.145.339.228.2
Diary Recordings (n=77, n=76, n=74, n=80)37.748.739.230.0
Treatment Success (n=76, n=75, n=74, n=78)72.485.364.959.0

Adverse events

Collected over Up to 8 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rabeprazole 10 mg—0/85 (0%)28/85 (32.9%)
Rabeprazole 20 mg—1/85 (1.2%)20/85 (23.5%)
Rabeprazole 40 mg—1/83 (1.2%)31/83 (37.3%)
Placebo—1/85 (1.2%)22/85 (25.9%)
Most frequent serious events
Most frequent serious events
EventRabeprazole 10 mgRabeprazole 20 mgRabeprazole 40 mgPlacebo
Abdominal DistensionGastrointestinal disorders0/851/851/831/85
Most frequent other events
Showing 10 of 15
Most frequent other events
EventRabeprazole 10 mgRabeprazole 20 mgRabeprazole 40 mgPlacebo
NasopharyngitisInfections and infestations10/857/8515/834/85
Back PainMusculoskeletal and connective tissue disorders3/850/850/834/85
StomatitisGastrointestinal disorders0/850/853/831/85
DiarrhoeaGastrointestinal disorders3/853/852/832/85
GastroenteritisInfections and infestations0/853/850/830/85
PharyngitisInfections and infestations0/851/851/833/85
Blood Triglycerides IncreasedInvestigations3/850/850/832/85
HeadacheNervous system disorders3/853/851/830/85
EnterocolitisGastrointestinal disorders0/850/852/830/85
Gastroenteritis ViralInfections and infestations0/850/852/830/85

Baseline characteristics

Per Protocol Set (PPS): was defined as those participants who complied with the study protocol. N= 338 participants were enrolled at study start. However, a total of 307 participants were included in PPS for efficacy evaluation.

Age, Continuous
Age, Continuous(years)Rabeprazole 10 mgRabeprazole 20 mgRabeprazole 40 mgPlaceboTotal
Mean46.9 ± 14.950.2 ± 16.546.4 ± 14.845.8 ± 15.547.3 ± 15.5
Sex: Female, Male
Sex: Female, Male(Participants)Rabeprazole 10 mgRabeprazole 20 mgRabeprazole 40 mgPlaceboTotal
Female43404744174
Male34362736133
08

Study locations

46 sites
  • Nagoya, Aichi, Japan
  • Chikushino, Fukuoka, Japan
  • Kitakyushu, Fukuoka, Japan
  • Maebashi, Gunma, Japan
  • Sapporo, Hokkaido, Japan
  • Kobe, Hyogo, Japan
  • Nishinomiya, Hyogo, Japan
  • Tsuchiura, Ibaraki, Japan
  • Takamatsu, Kagawa, Japan
  • Yokohama, Kanagawa, Japan
  • Sendai, Miyagi, Japan
  • Yufu, Oita, Japan
  • Nakagami, Okinawa, Japan
  • Hirakata, Osaka, Japan
  • Moriguchi, Osaka, Japan
  • Suita, Osaka, Japan
  • Takatsuki, Osaka, Japan
  • Karatsu, Saga, Japan
  • Kusatsu, Shiga, Japan
  • Izumo, Shimane, Japan
  • Fujieda, Shizuoka, Japan
  • Hamamatsu, Shizuoka, Japan
  • Otawara, Tochigi, Japan
  • Shimotsuga, Tochigi, Japan
  • Bunkyo, Tokyo, Japan
  • Mitaka, Tokyo, Japan
  • Nakano, Tokyo, Japan
  • Ota, Tokyo, Japan
  • Setagaya, Tokyo, Japan
  • Shibuya, Tokyo, Japan
  • Shinagawa, Tokyo, Japan
  • Akita, Japan
  • Fukuoka, Japan
  • Gifu, Japan
  • Hiroshima, Japan
  • Kagoshima, Japan
  • Kochi, Japan
  • Kumamoto, Japan
  • Kyoto, Japan
  • Miyazaki, Japan
  • Oita, Japan
  • Osaka, Japan
  • Saga, Japan
  • Saitama, Japan
  • Shizuoka, Japan
  • Yamagata, Japan
09

References and documents

Publications

  • Iwakiri R, Tominaga K, Furuta K, Inamori M, Furuta T, Masuyama H, Kanke K, Nagahara A, Haruma K, Kinoshita Y, Higuchi K, Takahashi S, Kusano M, Iwakiri K, Kato M, Hongo M, Hiraishi H, Watanabe S, Miwa H, Naito Y, Fujimoto K, Arakawa T. Randomised clinical trial: rabeprazole improves symptoms in patients with functional dyspepsia in Japan. Aliment Pharmacol Ther. 2013 Oct;38(7):729-40. doi: 10.1111/apt.12444. Epub 2013 Aug 20. PubMed 23957383 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2010
First posted
Mar 18, 2010
Start
Apr 2010
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Results first posted
Nov 19, 2013
Last update
Dec 24, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01089543
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Mar 18, 2010
Start date
Apr 2010
Primary completion
Aug 2011
Completion
Aug 2011
Results posted
Nov 19, 2013
Last update
Dec 24, 2013

Study contacts

Yoshiumi Okubo
study director · Eisai Co., Ltd.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion